Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.

Biochemical and biophysical research communications - 4 Mar 2017

Makino Yojiro, Yoon Jeong-Hwan, Bae Eunjin, Kato Mitsuyasu, Miyazawa Keiji, Ohira Tatsuo, Ikeda Norihiko, Kuroda Masahiko, Mamura Mizuko

Abstract excerpt

Cancer-associated inflammation develops resistance to the epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) harboring oncogenic EGFR mutations. Stat3-mediated interleukin (IL)-6 signaling and Smad-mediated transforming growth factor-β (TGF-β) signaling pathways play crucial regulatory roles in cancer-associated inflammation. However, mechanisms how...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Interleukin-6

Share to Intracellular Signaling Peptides and Proteins

Share to Quinazolines

Share to Smad3 Protein

Share to STAT3 Transcription Factor

Source

Identifiers

PMID: 28115165
DOI: 10.1016/j.bbrc.2017.01.093

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.PMID 28115165Read ↗

Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancerSemantic proximity Read ↗

Distinct expression and prognostic value of members of SMAD family in non-small cell lung cancer.Semantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivoSemantic proximity Read ↗

TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.Semantic proximity Read ↗

Emerging roles of suppressor of cytokine signaling 3 in human cancersSemantic proximity Read ↗

Smad7 Sustains Stat3 Expression and Signaling in Colon Cancer CellsSemantic proximity Read ↗

Loss of <i>Smad4</i> promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulationSemantic proximity Read ↗

Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma.Semantic proximity Read ↗

Knockdown of SMAD3 inhibits the growth and enhances the radiosensitivity of lung adenocarcinoma via p21 in vitro and in vivoSemantic proximity Read ↗

Novel activators and small-molecule inhibitors of STAT3 in cancerSemantic proximity Read ↗

Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.